AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The European Medicines Agency has finalised a safety review of medicines containing sibutramine. The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the risks of these medicines are greater than their benefits and recommended the suspension of marketing authorisations for these medicines across the European Union. Sibutramine-containing medicines are authorised as Reductil, Reduxade, and Zelium and other trade names in the European Union. They are used to promotes weight-loss in obese patients and overweight patients who …